Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Inventory (2019 - 2025)

Historic Change in Inventory for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to -$6.9 million.

  • Akebia Therapeutics' Change in Inventory fell 136587.16% to -$6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 5517.44%. This contributed to the annual value of $28.4 million for FY2024, which is 101726.99% up from last year.
  • Akebia Therapeutics' Change in Inventory amounted to -$6.9 million in Q3 2025, which was down 136587.16% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Inventory ranged from a high of $19.2 million in Q1 2021 and a low of -$24.5 million during Q4 2022
  • Moreover, its 5-year median value for Change in Inventory was $1.6 million (2023), whereas its average is $2.2 million.
  • The largest annual percentage gain for Akebia Therapeutics' Change in Inventory in the last 5 years was 76520.34% (2021), contrasted with its biggest fall of 420119.05% (2021).
  • Over the past 5 years, Akebia Therapeutics' Change in Inventory (Quarter) stood at -$10.3 million in 2021, then crashed by 136.59% to -$24.5 million in 2022, then soared by 148.18% to $11.8 million in 2023, then decreased by 27.88% to $8.5 million in 2024, then plummeted by 181.2% to -$6.9 million in 2025.
  • Its Change in Inventory was -$6.9 million in Q3 2025, compared to $7.7 million in Q2 2025 and $5.0 million in Q1 2025.